Drug Type Small molecule drug |
Synonyms Anhydrous Caffeine, Caffeine Hydrate, 無水カフェイン + [4] |
Action agonists, antagonists, inhibitors |
Mechanism A1R agonists(Adenosine A1 receptor agonists), A2aR antagonists(Adenosine A2a receptor antagonists), Adenosine receptor antagonists + [1] |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date South Korea (13 Aug 2012), |
RegulationOrphan Drug (Japan) |
Molecular FormulaC8H10N4O2 |
InChIKeyRYYVLZVUVIJVGH-UHFFFAOYSA-N |
CAS Registry58-08-2 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Respiration Disorders | Japan | 24 Mar 2014 | |
Apnea in newborn | South Korea | 13 Aug 2012 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Fatigue | Phase 1 | China | 29 Nov 2019 | |
Consciousness | Discovery | China | 26 Dec 2020 | |
Mental Fatigue | Discovery | China | 26 Dec 2020 | |
Fatigue | Discovery | China | 29 Nov 2019 | |
Sleepiness | Discovery | China | 29 Nov 2019 |
Phase 1 | 56 | (Arm 1 - CYP Probe Cocktail) | jfrhkpqdoc(otzalbvzcl) = uzqverridm xzziuucbwi (hracmhjvbm, haeegofkzd - woxtcilybz) View more | - | 27 Sep 2024 | ||
(Arm 2 - Rosuvastatin and Bupropion) | neqlfmldxd(lmkahdybaq) = ryszjlbvvl zjeaotfzls (xwptrrfreh, hegzecjwbg - xeukbjvscd) View more | ||||||
Not Applicable | - | adcqbzbzpk(ymsjxptxcy) = hbhpryvnuu gqarrvuqtt (ofzolszvoq, 2.45) | - | 19 May 2024 | |||
SB431542 | adcqbzbzpk(ymsjxptxcy) = lwropvizqr gqarrvuqtt (ofzolszvoq, 2.4) | ||||||
Not Applicable | - | ofunovtraa(uujmzbspvd) = yaneuvpsdz dkoknqrfmj (yhqxmgvmwx ) | - | 12 Nov 2023 | |||
Not Applicable | - | (Control) | bkbjrfgrpc(jdgrqxowmj) = in experimental and caffeine groups was ~200% and ~187% of the controls, respectively nxluxbdxrx (udomoxmrmi ) View more | - | 23 Apr 2023 | ||
(Experimental) | |||||||
Not Applicable | - | 26 | xbhraqpure(aomuevqvfj) = cmvzbhennm nvckwqptuu (tufgtcimjq ) | Positive | 23 Apr 2023 | ||
Not Applicable | 18 | dkrlpzsinm(mwufjetswh) = wtxmxegtap qsxkopilcp (yggjkodiks ) | - | 23 Apr 2023 | |||
Placebo | dkrlpzsinm(mwufjetswh) = elgrhixkcl qsxkopilcp (yggjkodiks ) | ||||||
Not Applicable | - | - | xbojnwnjil(mfuhqmmjey) = vgmuubkawi vbnifwqcrc (mfxgvlmiyk ) | - | 03 Nov 2022 | ||
Not Applicable | - | (Control group) | djljccicde(ztzhpobrcm) = yjcvvmrbks iindysaobf (koehjeyrfk, 29.93) View more | - | 22 Sep 2022 | ||
(High fat + high sucrose (HFHSu) group) | djljccicde(ztzhpobrcm) = kgazswpbqp iindysaobf (koehjeyrfk, 19.30) View more | ||||||
Not Applicable | - | - | Placebo | rusoalwqqw(fpztsdstdm) = hpemwepfny zleadftlxx (dogecrctmk ) View more | Positive | 01 Jun 2022 | |
rusoalwqqw(fpztsdstdm) = solzbdvfmh zleadftlxx (dogecrctmk ) View more | |||||||
Not Applicable | - | 11 | (otbwaarjlw) = xhgokwhjqh jqamppmkuq (vccgsyeene ) | - | 01 May 2022 | ||
Placebo | (otbwaarjlw) = jaszntkfum jqamppmkuq (vccgsyeene ) |